Social Capital Suvretta Holdings Corp. III
DNAC
NASDAQ Capital Market9.28
USD
-0.72
- -
CIK
0001850270
CUSIP
G8253W109
Return %
Stock
S&P500
1Y
-5.79
26.53
3Y
-8.21
76.60
5Y
-8.21
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Chamath Palihapitiya
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 2850 West Horizon Ridge Parkway Henderson NV United States of America 89052
- CIK
- 0001850270
- Similar Companies
- Business
- Social Capital Suvretta Holdings Corp. III (DNAC) operates as a blank check company, or special purpose acquisition company (SPAC), with no significant independent operations; it effects mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations with one or more businesses, primarily targeting opportunities in the biotechnology industry and the organ space sub-sector. Incorporated in 2021 and headquartered in Henderson, Nevada, the company focuses on healthcare-related targets without offering distinct products or services beyond its merger facilitation structure. Its geographic operations remain global in scope, aligned with potential target geographies in biotechnology. In a major development, Social Capital Suvretta Holdings Corp. III completed a definitive reverse merger business combination with ProKidney Corp. (formerly ProKidney LP) on July 11, 2022, valuing the combined entity at approximately $1.84 billion to $2.64 billion and resulting in a name change, ticker transition to PROK for the post-merger entity, and continued Nasdaq listing. The transaction included up to $825 million in gross proceeds, comprising a fully committed $575 million private investment in public equity (PIPE) led by $125 million from Social Capital, $50 million from ProKidney's existing investors, and additional institutional participation; it supported ProKidney's Phase 3 development of its lead renal autologous cell therapy (REACT) for chronic kidney disease, manufacturing expansion, and commercial preparation. No significant partnerships, funding rounds, acquisitions, or operational shifts have been reported for the entity in the last 1-2 years following the merger completion.
ProKidney to present at upcoming investor conferences
ProKidney to Present REACT® at 4th Annual CKD Summit
ProKidney To Become Publicly Traded Through Combination With Social Capital Suvretta Holdings Corp. III (DNAC)
ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal
ProKidney set to go public after SPAC merger that values combined company at $2.6 billion
2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?